XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results

British Journal of Cancer

Volumn 105, Issue 1, 2011, Pages 58-64

  Cassidy, J ^a   Clarke, S ^b   Diaz Rubio E ^c   Scheithauer, W ^d   Figer, A ^e   Wong, R ^f   Koski, S ^g   Rittweger, K ^h   Gilberg, F ⁱ   Saltz, L ^j  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^f ST BONIFACE GENERAL HOSPITAL   (Canada)

^g CROSS CANCER INSTITUTE   (Canada)

^h HOFFMANN LA ROCHE INC   (United States)

ⁱ F Hoffmann La Roche ^*  (Switzerland)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

5 fluorouracil folinic acid; capecitabine; colorectal cancer; overall survival; oxaliplatin

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PLACEBO;

ADULT; AGED; ARTICLE; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; FACTORIAL DESIGN; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79959740774     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.201     Document Type: Article

References (18)

1. Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, Martoni A, Grothey A, Hinke A, Schmiegel W, Schmoll HJ, Porschen R (2008) Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/ leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 26: 5910-5917
2. Cassidy J, Clarke S, Diaz Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L (2008a) A randomized phase III study of capecitabine plus oxaliplatin (XELOX) versus fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26: 2006-2012
3. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Sirzen F, Gilberg F, Saltz L (2008b) XELOX vs FOLFOX4: update of efficacy results from XELOX-1/NO16966, a randomized phase III trial of first-line treatment for patients (pts) with metastatic colorectal cancer (MCRC). Presented at the ASCO GI Cancers Symposium: Orlando, Florida, USA, 25-27 January (abstract 341)
4. Chu E, Schulman KL, Zelt S (2009) Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer. Cancer 115: 1412-1423
5. Comella P, Massidda B, Filippelli G, Farris A, Natale D, Barberis G, Maiorino L, Palmeri S, Condemi G, Southern Italy Cooperative Oncology Group (2009) Randomised trial comparing biweekly oxalipla-tin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/ leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. J Cancer Res Clin Oncol 135: 217-226
6. Cuppone F, Bria E, Sperduti I, Di Maio M, Carlini P, Milella M, Cognetti F, Terzoli E, Giannarelli D (2008) Capecitabine (CAP) versus 5-fluorouracil (FU) in combination with oxaliplatin (OX) as 1st-line chemotherapy (CT) for advanced colorectal cancer (ACRC): meta-analysis of randomized clinical trials (RCT). J Clin Oncol 26: 192s (Suppl; abstract 4056)
7. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947 (Pubitemid 30644117)
8. D́az-Rubio E, Tabernero J, Gómez-España A, Massut́ B, Sastre J, Chaves M, Abad A, Carrato A, Queralt B, Reina JJ, Maurel J, González-Flores E, Aparicio J, Rivera F, Losa F, Aranda E, Spanish Cooperative Group for the Treatment of Digestive Tumors Trial (2007) Phase III study of capecitabine plus oxaliplatin versus continuous infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors trial. J Clin Oncol 25: 4224-4230 (Pubitemid 47548562)
9. Di Leo A, Buyse M, Bleiberg H (2004) Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11. Ann Oncol 15: 545-549 (Pubitemid 38559586)
10. Ducreux M, Bennouna J, Hebbar M, Ychou M, Lledo G, Conroy T, Adenis A, Faroux R, Rebischung C, Bergougnoux L, Kockler L, Douillard JY, GI Group of the French Anti-Cancer Centers (2011) Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer 128: 682-690
11. Garrison L, Cassidy J, Saleh M, Lee F, Mena R, Fuloria J, Chang V, Ervin T, Stella P, Saltz L (2007) Cost comparison of XELOX compared to FOLFOX4 with or without bevacizumab (bev) in metastatic colorectal cancer. J Clin Oncol 25: 18S (Suppl, abstract 4074)
12. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 19: 2282-2292 (Pubitemid 32366981)
13. Porschen R, Arkenau H-T, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ, AIO Colorectal Study Group (2007) Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25: 4217-4223 (Pubitemid 47548561)
14. Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, Gollins S, Siu LL, Laguerre S, Cunningham D (2008) Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 19: 1720-1726
15. Saltz L, Clarke S, D́?az-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J (2008) Efficacy and safety of bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019
16. Scheithauer W, Cassidy J, Figer A, Wong R, Koski S, Lichinitser M, Yang T, Clarke S, Diaz-Rubio E, Garrison L (2007) A comparison of medical resource use for 4 chemotherapy regimens as first-line treatment for metastatic colorectal cancer (MCRC): XELOX vs. FOLFOX4 ± bevacizumab (A). J Clin Oncol 25: 18S (Suppl, abstract 4098)
17. Twelves C, Wong A, Nowacki MP, Abt M, Burris III H, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352: 2696-2704 (Pubitemid 41007824)
18. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P, Xeloda Colorectal Cancer Study Group (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097-4106 (Pubitemid 33049527)